Metronomic treatment of vinorelbine with oral capecitabine is tolerable in the randomized Phase 2 study XeNa including patients with HER2 non-amplified metastatic breast cancer

Breast cancer

(2019) Nadia Harbeck et al.   Nature Reviews Disease Primers

Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study

(2017) Marina E. Cazzaniga et al.   TUMORI

Efficacy and Safety of Vinorelbine-Capecitabine Oral Metronomic Combination in Elderly Metastatic Breast Cancer Patients: VICTOR-1 Study

(2017) Marina E. Cazzaniga et al.   TUMORI JOURNAL

The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis

(2017) Yangyang Liu et al.   PLoS One

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

(2016) M. E. Cazzaniga et al.   BREAST CANCER RESEARCH AND TREATMENT

Systemic Therapy of Advanced/Metastatic Breast Cancer - Current Evidence and Future Concepts

(2016) Cornelia Liedtke et al.   Breast Care

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development

(2016) Marina E Cazzaniga et al.   Future Oncology

Clinical overview of metronomic chemotherapy in breast cancer

(2015) Elisabetta Munzone et al.   Nature Reviews Clinical Oncology

Metronomic therapy and breast cancer: A systematic review

(2014) Emilia Montagna et al.   CANCER TREATMENT REVIEWS

Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study

(2013) Evangelos Briasoulis et al.   BMC CANCER

A phase I trial of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer

(2011) Zacharenia Saridaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial

(2009) N Tubiana-Mathieu et al.   BRITISH JOURNAL OF CANCER

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes

(2009) Alison Jones et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Dose-Ranging Study of Metronomic Oral Vinorelbine in Patients with Advanced Refractory Cancer

(2009) E. Briasoulis et al.   CLINICAL CANCER RESEARCH

METRONOMIC CHEMOTHERAPY. CHANGING THE PARADIGM THAT MORE IS BETTER

(2009) O.Graciela Scharovsky et al.   Current Oncology

Vinorelbine as first-line or second-line therapy for advanced breast cancer: A Phase I-II trial by the Danish Breast Cancer Co-operative Group

(2008) Sven T. Langkjer et al.   ACTA ONCOLOGICA

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER